Resistance to molecularly targeted therapy in non-small-cell lung cancer

The discovery of oncogenic driver gene mutations, including epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion, ROS proto-oncogene 1 (ROS1) fusion, and ret proto-oncogene (RET) fusion, has led to the development of molecularly targeted therapy for non-small-cel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory investigation 2019-01, Vol.57 (1), p.20-26
Hauptverfasser:	Asao, Tetsuhiko, Takahashi, Fumiyuki, Takahashi, Kazuhisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired resistance ALK Anaplastic Lymphoma Kinase - genetics Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - therapy EGFR Epidermal Growth Factor - genetics Gene Fusion Humans Lung cancer Lung Neoplasms - genetics Lung Neoplasms - therapy Molecular Targeted Therapy Molecularly targeted therapy Mutation Protein-Tyrosine Kinases - genetics Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins c-ret - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!